These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 39135672

  • 1. Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment.
    Xia D, Qian Q, Wang S, Dong X, Liu Y.
    Int J Nanomedicine; 2024; 19():7983-7996. PubMed ID: 39135672
    [Abstract] [Full Text] [Related]

  • 2. Effect of alendronate on the femoral metaphyseal defect under carbamazepine in ovariectomized rats.
    Zhang R, Yang M, Li Y, Liu H, Ren M, Tao ZS.
    J Orthop Surg Res; 2021 Jan 06; 16(1):14. PubMed ID: 33407695
    [Abstract] [Full Text] [Related]

  • 3. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M, Shan J, Xu H, Xia G, Xu Q, Quan K, Liu X, Dai M.
    J Ethnopharmacol; 2021 Aug 10; 276():114176. PubMed ID: 33933570
    [Abstract] [Full Text] [Related]

  • 4. Polyaptamer-Driven Crystallization of Alendronate for Synergistic Osteoporosis Treatment through Osteoclastic Inhibition and Osteogenic Promotion.
    Yang X, Fan Y, Liang J, Cao R, Zhang B, Li J, Li Z, He S, Liu N, Du J, Hu Y.
    ACS Nano; 2024 Aug 20; 18(33):22431-22443. PubMed ID: 39103298
    [Abstract] [Full Text] [Related]

  • 5. Hydroxychloroquine and a low antiresorptive activity bisphosphonate conjugate prevent and reverse ovariectomy-induced bone loss in mice through dual antiresorptive and anabolic effects.
    Yao Z, Ayoub A, Srinivasan V, Wu J, Tang C, Duan R, Milosavljevic A, Xing L, Ebetino FH, Frontier AJ, Boyce BF.
    Bone Res; 2024 Sep 05; 12(1):52. PubMed ID: 39231935
    [Abstract] [Full Text] [Related]

  • 6. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
    Kostenuik PJ, Smith SY, Samadfam R, Jolette J, Zhou L, Ominsky MS.
    J Bone Miner Res; 2015 Apr 05; 30(4):657-69. PubMed ID: 25369992
    [Abstract] [Full Text] [Related]

  • 7. The bone resorption inhibitors odanacatib and alendronate affect post-osteoclastic events differently in ovariectomized rabbits.
    Jensen PR, Andersen TL, Pennypacker BL, Duong LT, Delaissé JM.
    Calcif Tissue Int; 2014 Feb 05; 94(2):212-22. PubMed ID: 24085265
    [Abstract] [Full Text] [Related]

  • 8. MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice.
    Mao Z, Zhu Y, Hao W, Chu C, Su H.
    IUBMB Life; 2019 Dec 05; 71(12):1916-1928. PubMed ID: 31317664
    [Abstract] [Full Text] [Related]

  • 9. Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats.
    Wang Y, Huang P, Tang PF, Chan KM, Li G.
    J Orthop Surg Res; 2011 Jul 13; 6():34. PubMed ID: 21752290
    [Abstract] [Full Text] [Related]

  • 10. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
    Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL.
    J Biol Chem; 2010 Sep 03; 285(36):28164-73. PubMed ID: 20558734
    [Abstract] [Full Text] [Related]

  • 11. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
    Sugimoto M, Futaki N, Harada M, Kaku S.
    Bone; 2013 Jan 03; 52(1):181-8. PubMed ID: 23041510
    [Abstract] [Full Text] [Related]

  • 12. Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity.
    Lin X, Yuan G, Yang B, Xie C, Zhou Z, Liu Y, Liu Z, Wu Z, Akimoto Y, Li N, Xu R, Song F.
    Phytomedicine; 2024 Jul 03; 129():155559. PubMed ID: 38579642
    [Abstract] [Full Text] [Related]

  • 13. Effect of Taraxaci Herba on Bone Loss in an OVX-Induced Model through the Regulation of Osteoclast Differentiation.
    Heo J, Kim M, Kim JH, Shin H, Lim SE, Jung HS, Sohn Y, Ku J.
    Nutrients; 2022 Oct 18; 14(20):. PubMed ID: 36297038
    [Abstract] [Full Text] [Related]

  • 14. Effects of alendronate on bone formation and osteoclastic resorption after implantation of beta-tricalcium phosphate.
    Tanaka T, Saito M, Chazono M, Kumagae Y, Kikuchi T, Kitasato S, Marumo K.
    J Biomed Mater Res A; 2010 May 18; 93(2):469-74. PubMed ID: 19582838
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use.
    Tsuda E, Fukuda C, Okada A, Karibe T, Hiruma Y, Takagi N, Isumi Y, Yamamoto T, Hasegawa T, Uehara S, Koide M, Udagawa N, Amizuka N, Kumakura S.
    Bone; 2022 Feb 18; 155():116241. PubMed ID: 34715394
    [Abstract] [Full Text] [Related]

  • 17. Ångstrom-scale gold particles loaded with alendronate via alpha-lipoic acid alleviate bone loss in osteoporotic mice.
    Gao W, Li JJ, Shi J, Lan H, Guo Y, Fu D.
    J Nanobiotechnology; 2024 Apr 30; 22(1):212. PubMed ID: 38689294
    [Abstract] [Full Text] [Related]

  • 18. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
    Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.
    Endocrinology; 2011 Sep 30; 152(9):3312-22. PubMed ID: 21733832
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment.
    Xu Q, Zhan P, Li X, Mo F, Xu H, Liu Y, Lai Q, Zhang B, Dai M, Liu X.
    J Cell Mol Med; 2021 Nov 30; 25(21):10126-10139. PubMed ID: 34651433
    [Abstract] [Full Text] [Related]

  • 20. Preparation of an injectable depot system for long-term delivery of alendronate and evaluation of its anti-osteoporotic effect in an ovariectomized rat model.
    Bae J, Park JW.
    Int J Pharm; 2015 Mar 01; 480(1-2):37-47. PubMed ID: 25595570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.